{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T05:03:24Z","timestamp":1784351004107,"version":"3.55.0"},"reference-count":13,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2026,6,30]]},"DOI":"10.5582\/ddt.2026.01015","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T22:10:04Z","timestamp":1781993404000},"page":"269-272","source":"Crossref","is-referenced-by-count":0,"title":["Analytical method validation and feasibility of salivary pregabalin measurement in Japanese volunteers: A pilot study"],"prefix":"10.5582","volume":"20","author":[{"given":"Hina","family":"Itoi","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacodynamics and Toxicology Analytics, Meiji Pharmaceutical University, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Gando","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacodynamics and Toxicology Analytics, Meiji Pharmaceutical University, Tokyo, Japan."},{"name":"Department of Pharmacy, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Yasu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacodynamics and Toxicology Analytics, Meiji Pharmaceutical University, Tokyo, Japan."},{"name":"Department of Pharmacy, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan."},{"name":"Bokutoh Hospital-Meiji Pharmaceutical University Joint Research Center, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Bokutoh Hospital-Meiji Pharmaceutical University Joint Research Center, Tokyo, Japan."},{"name":"Department of Hematology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bockbrader HN, Radulovic LL, Posvar EL, Strand JC, Alvey CW, Busch JA, Randinitis EJ, Corrigan BW, Haig GM, Boyd RA, Wesche DL. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol. 2010; 50:941-950.","DOI":"10.1177\/0091270009352087"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Patsalos PN. Pregabalin. In: Antiseizure Medication Interactions. Springer, Cham, Switzerland, 2022; pp. 133-136.","DOI":"10.1007\/978-3-030-82790-8_24"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Resztak M, Czyrski A, Sobiak J. Saliva as a matrix for therapeutic drug monitoring and disease biomarkers in children and adolescents. Pharmacol Rep. 2025; 77:921-961.","DOI":"10.1007\/s43440-025-00732-7"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Parkin GM, McCarthy MJ, Thein SH, Piccerillo HL, Warikoo N, Granger DA, Thomas EA. Saliva testing to monitor therapeutic lithium levels: identification of clinical and environmental covariates and incorporation into a prediction model. Bipolar Disord. 2021; 23:679-688.","DOI":"10.1111\/bdi.13128"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Rather MY, Farhat S, Rather MY. Use of saliva as an alternative matrix to serum\/plasma for therapeutic drug monitoring using reverse-phase HPLC. Clin Ther. 2021; 43:2127-2135.","DOI":"10.1016\/j.clinthera.2021.10.012"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Idkaidek N, Hamadi S, El-Assi M, Al-Shalalfeh A, Al-Ghazawi A. Saliva versus plasma therapeutic drug monitoring of pregabalin in Jordanian patients. Drug Res (Stuttg). 2018; 68:596-600.","DOI":"10.1055\/a-0600-2113"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Klancke J, Gajendran J, Guillot A, Schichtel J, Tuereli A. Dissolution testing of orally disintegrating tablets. J Pharm Pharmacol. 2012; 64:911-918.","DOI":"10.1111\/j.2042-7158.2012.01473.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Almukainzi M, Araujo GLB, L\u00f6benberg R. Orally disintegrating dosage forms. J Pharm Investig. 2018; 48:19-30.","DOI":"10.1007\/s40005-018-0408-2"},{"key":"9","unstructured":"9. U.S. Food and Drug Administration. Bioanalytical Method Validation: Guidance for Industry. May 2018. <i>https:\/\/www.fda.gov\/media\/70858\/download<\/i> (accessed 15 January 2026)"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kanda Y. Investigation of the freely available easy-to-use software &quot;EZR&quot; for medical statistics. Bone Marrow Transplant. 2013; 48:452-458.","DOI":"10.1038\/bmt.2012.244"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Xu F, Laguna L, Sarkar A. Ageing-related changes in quantity and quality of saliva: Where do we stand in our understanding? J Texture Stud. 2019; 50:27-35.","DOI":"10.1111\/jtxs.12356"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Vandenberghe-Descamps M, Labour\u00e9 H, Prot A, Septier C, Tournier C, Feron G, Sulmont-Rosse C. Salivary flow decreases in healthy elderly people independently of dental status and drug intake. J Texture Stud. 2016; 47:353-360.","DOI":"10.1111\/jtxs.12191"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Morita I, Morioka H, Abe Y, Nomura T, Nakashima S, Sugiura I, Inagawa Y, Kondo Y, Kameyama C, Kondo K, Kobayashi N. Discordance between hyposalivation and xerostomia among community-dwelling older adults in Japan. PLoS One. 2023; 18:e0282740.","DOI":"10.1371\/journal.pone.0282740"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/3\/20_2026.01015\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:26:30Z","timestamp":1784348790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/3\/20_2026.01015\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2026.01015","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"article-number":"2026.01015"}}